Leukemic lineage switch in a t(8;22)(p11.2;q11.2)/BCR-FGFR1-rearranged myeloid/lymphoid neoplasm with RUNX1 mutation - diagnostic pitfalls and clinical management including FGFR1 inhibitor pemigatinib. Article uri icon

Overview

publication date

  • September 16, 2019

Research

keywords

  • Core Binding Factor Alpha 2 Subunit
  • Leukemia, Myeloid
  • Morpholines
  • Pyrimidines
  • Pyrroles

Identity

Scopus Document Identifier

  • 85073817589

Digital Object Identifier (DOI)

  • 10.1080/10428194.2019.1660975

PubMed ID

  • 31524018

Additional Document Info

volume

  • 61

issue

  • 2